Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vanda Pharmaceutical (VNDA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 597,680
  • Shares Outstanding, K 43,280
  • Annual Sales, $ 109,930 K
  • Annual Income, $ -39,870 K
  • 36-Month Beta 1.41
  • Price/Sales 4.28
  • Price/Book 4.56

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.20 +0.38%
on 01/19/17
16.65 -20.42%
on 12/21/16
-3.20 (-19.45%)
since 12/20/16
3-Month
13.20 +0.38%
on 01/19/17
17.60 -24.72%
on 11/25/16
-2.69 (-16.88%)
since 10/20/16
52-Week
6.91 +91.75%
on 02/11/16
18.00 -26.39%
on 09/22/16
+4.46 (+50.74%)
since 01/20/16

Most Recent Stories

More News
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017

Conference Call and Webcast to Follow

Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics

For today, Stock-Callers.com takes a closer look at some Biotech equities: Cara Therapeutics Inc. (NASDAQ: CARA), Heat Biologics Inc. (NASDAQ: HTBX), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Opexa...

Abbott Labs to Close St. Jude Acquisition Later this Week

Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.

Immunomedics Completes Enrollment In Cancer Drug Study

Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.

Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate

Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.

Prima (PBMD) Reports Favorable Initial Melanoma Study Data

Prima (PBMD) announced interim data from the TACTI-mel program on IMP321 for the treatment of patients with unresectable or metastatic melanoma.

Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA

Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.

Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout

Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ)....

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Support & Resistance

2nd Resistance Point 13.72
1st Resistance Point 13.48
Last Price 13.25
1st Support Level 13.13
2nd Support Level 13.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.